About-Evergreen Therapeutics, Inc.

About Evergreen

Focus on Unmet Clinical Needs and Achieve Medical Value

Established in August 2019 in Shenzhen, China, Evergreen Therapeutics is an international, innovative, clinical-stage pharmaceutical company. It is committed to meeting the clinical needs and achieving medical value to benefit patients worldwide. Headquartered in Shenzhen, Evergreen has office and laboratory in the United States. Established for more than two years, Evergreen has developed rapidly and has become a leader in efficient R&D of Chinese innovative pharmaceutical enterprise and a pioneer in internationalization of Chinese innovative pharmaceutical enterprise.

Evergreen applies artificial intelligence (AI) and has always adhered to a global and differentiated development strategy, focusing on the research and development of innovative drugs in the fields of autoimmunity, tumor immunity, chronic diseases, ophthalmology, etc. While exploring new targets, the company also actively develops new indications for existing drugs. At present, the company has 90 authorized patents and 12 product pipelines, and has been granted for 17 patents. Five drugs have entered clinical stage. The patents cover major global pharmaceutical markets such as China, theUnited States, Europe, and Japan. Several drugs are in the pipeline, ranging from treatment or COVID-19, age-related macular degeneration, idiopathic interstitial pneumonia, and dry eye; the market for these drugs looks promising.

Evergreen was founded by highly experienced pharmaceutical executives. Nearly all of senior management and R&D team members have experiences in the US FDA or at top international pharmaceutical companies. The advisory team also consists of world's top experts. While the company is constantly improving its internal research and development capabilities, the management team is also actively planning and hosting highly recognized,international medical conferences to discuss and promote new drug development and innovation in the pharmaceutical industry.

With dual headquarters in Shenzhen, China, and Maryland, USA, Evergreen actively engages in international exchanges and investor communication while taking advantage of its location in the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.

10 Product Pipelines

90+ Patents Licensing

5 Clinical Drug Candidates

Development History

2022

02-04:

The new molecular drug EG-301 discovered by Eglin AI platform has been approved by the US FDA to enter Phase II clinical practice

03-07:

Anti neocrown drug EG-009A was approved to enter the second phase clinical trial in Argentina

2021

03-15:

Raised RMB 100 million in Series A financing to develop Covid-19 clinical drugs

07-01:

Third Quarter - EG009A was officially in Phase II clinical trials

07-19:

ry Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer

08-11:

The U.S. Food and Drug Administration (FDA) has approved the entry of Eg-007 into a pivotal phase III clinical trial

09-14:

COVID-19 Drug EG-009A has been approved for phase II clinical trials in India

2020

01-01:

Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO

09-23:

EG-009 was officially approved by the FDA for phase I clinical trials

10-13:

EG-001 was officially approved by the FDA for phase I clinical trials

10-27:

EG-009A was officially approved by the FDA for phase II clinical trials

12-10:

Phase I clinical trials launched: an oral treatment for COVID-19

2019

08-26:

Evergreen Therapeutics Inc. was formally established

09-05:

Cooperate with McGill University in the research and development of respiratory drugs

2022

02-04:

The new molecular drug EG-301 discovered by Eglin AI platform has been approved by the US FDA to enter Phase II clinical practice

03-07:

Anti neocrown drug EG-009A was approved to enter the second phase clinical trial in Argentina

2021

03-15:

Raised RMB 100 million in Series A financing to develop Covid-19 clinical drugs

07-01:

Third Quarter - EG009A was officially in Phase II clinical trials

07-19:

ry Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer

08-11:

The U.S. Food and Drug Administration (FDA) has approved the entry of Eg-007 into a pivotal phase III clinical trial

09-14:

COVID-19 Drug EG-009A has been approved for phase II clinical trials in India

2020

01-01:

Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO

09-23:

EG-009 was officially approved by the FDA for phase I clinical trials

10-13:

EG-001 was officially approved by the FDA for phase I clinical trials

10-27:

EG-009A was officially approved by the FDA for phase II clinical trials

12-10:

Phase I clinical trials launched: an oral treatment for COVID-19

2019

08-26:

Evergreen Therapeutics Inc. was formally established

09-05:

Cooperate with McGill University in the research and development of respiratory drugs

Management Team

Tom Du, M.D., Ph.D.

Founder, Chairman

Tom Du, M.D., Ph.D.

He graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.

The Team Has Strong Independent Research And Development Capabilities

Top Management
AI Research Team
Drug R&D Team
Business Team

David Du, Ph.D

Co-founder, CEO

David Du, Ph.D

He received his PhD in Biochemistry, University of Florida in the USA. He also did postdoctoral research at the National College of Medicine in the United States. Former FDA review officer, senior executives of many large and medium-sized international pharmaceutical companies, experts familiar with the entire process of FDA and global drug development, manufacturing, quality management, clinical design, drug product marketing application, and global post-marketing management of drug products. Dr. Du used to be a CMC reviewer of FDA, responsible for IND and BLA review of biological drugs. Subsequently, he worked at Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis, BMS, NPS and other multinational pharmaceutical companies. In the pharmaceutical industry more than 20 years of work, prevent new doctor for four biological medicine licenses approved by FDA, two biological drug approvals in the European Union and Canada, and countless IND in the United States, China, Europe, and other state approval, related to the size of the molecules, cells and genes, soluble tumor virus and medical devices and other various types of products. He has experience in managing medicines marketed in more than 30 countries.

Charles Lee, M.D, Ph.D

Co-founder, CMO

Charles Lee, M.D, Ph.D

He graduated from Xi 'an Jiaotong University School of Medicine and received his Master's degree in hospital Administration and doctor of Public Health degree from the University of Alabama Birmingham, USA. He did three years of residency at the University of Chicago Medical Center and obtained the American Physician license and the American Clinical Pathology Specialist certification. He used to be a senior medical reviewer of THE US Food and Drug Administration (FDA), and was the first overseas Chinese to enter FDA's clinical review as a doctor. Dr. Changqing Li has extensive experience in phase I-IV global clinical trials in oncology, immunotherapy, anti-inflammatory, gastrointestinal diseases, and gynecological diseases. He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing overall solutions for global drug development, regulatory registration, clinical strategy and risk management.

Sunny Yang

CFO

Sunny Yang

Master of Economics from Central University of Finance and Economics, MBA from Nanyang Technological University, Singapore. After that, She served as founding partner and general manager in many financial institutions including Pivot Capital and Jinhui Xingye Investment Management. Engaged in investment banking consulting business for 15 years, she has rich experience in the fields of corporate financing, M&A and listing financing. Ms. Yang has also made many achievements in the field of medicine, once served as the Deputy Secretary General of the China Pharmaceutical Industry Association and is currently the Vice President and Secretary General of the Gene Branch of the China Association of Traditional Chinese Medicine Information.

Bill Wang, Ph.D.

Director of AI Biometric Information

Bill Wang, Ph.D.

Graduated from Beijing Normal University, received his Ph.D. in Biology from Uppsala University, and postdoctoral fellow at Kanarinska Institutet, Sweden; He was a former Director of the Bioinformatics Centre at the University of Melbourne, and is a scientist with many years of experience in bioinformatics engineering and genomics research.

Xuhan Liu Ph.D

Associate Director of AI algorithms

Xuhan Liu Ph.D

Graduated from the Academy of Science of Leiden University in the Netherlands, he obtained a Ph.D. in Computational Medicinal Chemistry, and worked at Beijing Oriental Yamei Gene Technology Co., Ltd. as a Bioinformatics Engineer. His main research direction is artificial intelligence design of new drug molecules, and he has in-depth research in the fields of data mining, algorithms, protein engineering, and molecular simulation.

Cheryl Rowe-Rendleman, Ph.D.

VP, Clinical Science

Cheryl Rowe-Rendleman, Ph.D.

Graduated from Princeton University with a Ph.D. from the University of Houston; Postdoctoral Fellow in Developmental and Degenerative Diseases at the University of Texas School of Medicine and the University of San Francisco School of Medicine; Founder and CEO of Omar Consulting, Medical Director of IntraMed Educational Group, and Senior Scientist at InSite Vision Corporation. Dr. Rowe-Rendleman is a clinical development expert with over 15 years experience in pharmaceutical field.

Patrick McGrath, Ph.D

VP, Clinical Operation

Patrick McGrath, Ph.D

PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.

Tao Hu, Ph.D.

Director of Pharmacology

Tao Hu, Ph.D.

Bachelor of Pharmacy, Master of Pharmacology, Peking University Health Science Center; Doctor of Biomedical Science, Chinese University of Hong Kong. Postdoctoral fellow, School of Pharmacy, University of Washington, 2015-2018. Scientist, Clinical Pharmacology Division, FDA, 2018-2020. He has published more than 20 research papers in the fields of pharmacology, pharmacokinetics and drug interactions, and participated in editing and writing 2 academic papers. He has rich experience in pharmacological experiment design and drug mechanism research.

Shanshan Li, Ph.D.

Director of CMC

Shanshan Li, Ph.D.

Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.

Kevin Wang

CBO

Kevin Wang

Graduated from the University of Miami with an MBA and a Master of Biostatistics. He has more than 15 years of experience in the pharmaceutical industry and more than 5 years of business development experience. He has worked in US-listed pharmaceutical companies and pharmaceutical consulting companies for many years, and has worked in AOB and Humphrey Pharmaceutical Consulting, serving as Deputy General Manager of Business Development and Assistant to the president. He is familiar with the daily operation of innovative pharmaceutical companies and has extensive experience in business cooperation, patent planning and technology transfer of pharmaceutical projects.

James Diao

Senior Director of Public Affairs

James Diao

Graduated from Newcastle University Business School; and received a MSc in Project Management from the University of Manchester; with PRINCE2 certified for project management by UK government. He started his healthcare career at Omnicom Health Group AP and served as Executive Assistant; he provided market consulting services for several MNCs including MSD, Pfizer and Novartis. Prior to joining Evergreen, he was the Vice President of Continental Capital and has abundant experience in the research and investment field of the pharmaceutical industry.

Minghan Cui

BD Associate Director

Minghan Cui

Master of Pharmaceutical Engineering, South China Agricultural University; Used to be the marketing manager of clinical Coordination Department of Hengrui Pharmaceutical. Pfizer China Cardiovascular Group SMICS; Researcher of Pharmaceutical Research Institute of Guangyao Baiyunshan Pharmaceutical General Factory.

Bertram Cai

BD Associate Director

Bertram Cai

Master of Biochemistry and Molecular Biology, Anhui University. Worked for Pfizer China cardiovascular and anti-inflammatory and analgesic unit as SMICS; SMICS for the full product of Bo Ruilin Group.

Scientific Advisory Committee

Florence Houn, M.D. Clinical Development Consultant of Anticancer and Other Drugs

Dr. Houn is a former outstanding leader of FDA, having served as the Office Director of CDER, CBER, and CDRH for 15 years. She also served as executive in MNCs, and is a former professor at Johns Hopkins University and an oncologist. Dr. Houn is currently a clinical development consultant of anticancer and other drugs in Evergreen.

Ruyi He M.D.Medical Consultant for New Drug Development

Chief Scientist of SDIC Fund; The first senior talent introduced from overseas by the CFDA as the Chief Scientist; Dr. Ruyi He has over 17 years of experience in FDA clinical review and approval; He is currently the CMO and Head of Clinical Research of Remegen Biotech.

James Martin, M.D.Clinical Development Consultant in Basic Science and Respiratory Diseases

Dr. Martin is a renowned respiratory specialist, former chief of internal medicine at McGill University, former director of the Respiratory Disease Institute, and a leading expert in asthma and COPD, especially in asthma pathophysiology research. Currently he serves as a consultant of Evergreen on basic science and clinical trials of respiratory diseases.

Paolo Baroldi, M.D., Ph.DClinical Development Consultant of Immunology

PhD in Clinical Pharmacology, Diploma from Harvard Business School Executive Education. An outstanding physician and clinical pharmacologist with more than 35 years of experience in pharmaceutical industry and drug development led the R&D of 25 new drugs including epirubicine, imatinib. Expertise in a wide variety of therapeutic areas.

Richard Moore, M.D. Clinical Development Consultant in Oncology

Dr. Moore is the Chair of Department of Gynecologic Oncology at the University of Rochester Medical Center. Former chair of the Department of Gynecologic Oncology at Brown University. He is an internationally recognized expert who uses biomarkers to detect ovarian cancer. Dr. Moore has a strong professional relationship with Evergreen and currently serves as the clinical development consultant in oncology.

Robert Malone, M.D. Clinical Development Consultant of COVID-19 Drugs

Dr. Malone is renowned infectious disease expert. He received M.D. degree in Northwestern University, was postdoctoral fellow at Harvard University. He has more than 20 years of experience in clinical development of new drugs and participated in the design and supervision of about 40 clinical trials from Phase I to Phase III. Currently he is serving as a consultant of Evergreen on novel Coronavirus treatment drug development.

James Handa, M.D. Clinical Development Consultant for Fundus Diseases

Director of the Department of Retinology at the Johns Hopkins University School of Medicine, Wilmer Institute of Ophthalmology; Doctor of Medicine from the University of Pennsylvania School of Medicine; Worked at Wells Eye Hospital in Philadelphia, Duke University Eye Center, and UCLA Children's Hospital; He has studied ophthalmic retinal, vitreous, and ophthalmic tumor diseases for many years, published hundreds of scientific research articles, and developed animal models of dry AMD.

Roy Vaz, Ph.D.Consultant for AI-assisted Drug Development

Head of Structural Biology, Computer-Aided Drug Design, and Chemoinformatics at Sanofi, US ; Dr. Vaz has extensive experience in AI drug discovery in the fields of rare diseases, immunology, and neuroscience, providing computer-aided drug design for projects in these areas.

About EvergreenABOUT EVERGREEN